One Baxter Parkway,
Deerfield,
Illinois 60015
United States,
(224) 948-2000
www.baxter.com
Baxter International Inc. develops, manufactures and markets drugs and medical products for people with a variety of medical conditions. Baxter's operations are comprised of the BioScience and Medical Products segments. The BioScience business processes recombinant and plasma-based proteins to treat hemophilia and other bleeding disorders; plasma-based therapies to treat immune deficiencies, alpha-1 antitrypsin deficiency, burns and shock, and other chronic and acute blood-related conditions; biosurgery products; and select vaccines. The Medical Products business manufactures intravenous (IV) solutions and administration sets, premixed drugs and drug-reconstitution systems, pre-filled vials and syringes for injectable drugs, IV nutrition products, infusion pumps, and inhalation anesthetics. The business also provides products and services related to pharmacy compounding, drug formulation and packaging technologies. In addition, the Medical Products business provides products and services to treat end-stage renal disease, or irreversible kidney failure. Baxter International was established in 1931 and is headquartered in Deerfield, Illinois.
| Year | ≤ '12 | '13 | '14 | '15 | '16 | '17 | T | |
|---|---|---|---|---|---|---|---|---|
| Buy (1.0/yr) | # | 10 | 2 | 1 | 1 | 1 | - | 15 |
| vol | $2.6B | $3.9B | $70M | $225M | $625M | $7.4B | ||
| Sell (0.4/yr) | # | 3 | - | 1 | 1 | - | - | 5 |
| vol | $22M | $635M | $657M | |||||
| 20 | ||||||||
| Financial | Deals |
|---|---|
|
Sign-up to View
|
1 |
| Legal | Deals |
|---|---|
| Join to Access. | |
| Buy | # | TOTAL |
|---|---|---|
| > $1B | Sign-up to View | |
| $100M to $1B | Sign-up to View | |
| < $100M | Sign-up to View | |
| TOTAL | Sign-up to View | |
| Largest |
Gambro AB $3.9B (2013-09-06) |
|
| Sell | # | Total |
|---|---|---|
| > $1B | Sign-up to View | |
| $100M to $1B | Sign-up to View | |
| < $100M | Sign-up to View | |
| Total | Sign-up to View | |
| Largest |
Baxter International Inc. - Marketed Vaccines $635M (2014-07-30) |
|
According to our data here at Mergr, Baxter International has acquired 17 companies, including 6 in the last 5 years. A total of 5 acquisitions came from private equity firms. It has also divested 5 assets.
Baxter International’s largest acquisition to date was in 2013, when it acquired Gambro AB for $3.9B. It’s largest disclosed sale occurred in 2014, when it sold Baxter International - Marketed Vaccines to Pfizer for $635M. Baxter International has acquired in 7 different US states, and 6 countries. The Company’s most targeted sectors include medical products (54%) and healthcare services (20%).
When analyzing the medical products sector as a whole, according to Mergr, in the last 3 years, there are 330 medical products companies that have made at least 1 acquisition, 17 have acquired at least 5 companies, and 4 have acquired more than 10 companies. The most prolific strategic medical products acquirer over the past 3 years is Medtronic, with 12 acquisitions. The most prolific private equity acquirer in the medical products sector over the past 3 years is SHS GmbH with 7 platform acquisitions.
Join Mergr and gain access to Baxter International’s M&A summary, the M&A summaries of companies just like it, as well as recent M&A activity in the medical products sector.
No obligation. Cancel anytime.
